HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 12:48 pm IST
Share
HLB Therapeutics Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 384.76 million compared to negative sales of KRW 0.0008 million a year ago. Net loss was KRW 3,030.69 million compared to KRW 2,268.74 million a year ago. Basic loss per share from continuing operations was KRW 47.343 compared to KRW 41.0628 a year ago. Diluted loss per share from continuing operations was KRW 47.343 compared to KRW 41.0628 a year ago. Basic loss per share was KRW 47.343 compared to KRW 41.0628 a year ago.
For the nine months, sales was KRW 407.86 million compared to negative sales of KRW 0.0002 million a year ago. Net loss was KRW 4,995.76 million compared to KRW 10,721.51 million a year ago. Basic loss per share from continuing operations was KRW 77.7778 compared to KRW 193.7198 a year ago. Diluted loss per share from continuing operations was KRW 77.7778 compared to KRW 193.7198 a year ago. Basic loss per share was KRW 77.7778 compared to KRW 193.7198 a year ago.
HLB Therapeutics Co Ltd, formerly G-treeBNT Co Ltd, is a Korea-based company engaged in the research and development of optimized multimedia software for various digital appliances including cellular phones. Along with its affiliates, the Company operates solution business segment, which provides embedded graphic user interface (GUI) software solutions as well as wired and wireless integration multimedia platform solutions. Its embedded GUI products include FXUI-two-dimensional (2D), FXUI-three-dimensional (3D) and FX Studio, which are used for cellular phones and embedded equipment. Its wired and wireless integration multimedia platform products include FX-Flash and others, which are used for cellular phones and other mobile devices; electronic components manufacturing business segment, which provides transformers, pumps, motors and others, as well as educational and bio pharmaceutical business segments.
HLB THERAPEUTICS CO.,LTD. 
